RhumbLine Advisers
VIVO

RhumbLine Advisers’s Meridian Bioscience Inc VIVO Stock Holding History

RhumbLine Advisers’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-96,989
Closed -$3.22M – 2996
2022
Q4 		$3.22M Buy
96,989
+1,929
+2% +$62.1K ﹤0.01% 1546
2022
Q3 		$3M Sell
95,060
-19,347
-17% -$626K ﹤0.01% 1541
2022
Q2 		$3.48M Sell
114,407
-6,244
-5% -$169K 0.01% 1459
2022
Q1 		$3.13M Sell
120,651
-5,739
-5% -$137K ﹤0.01% 1581
2021
Q4 		$2.58M Buy
126,390
+1,778
+1% +$34.1K ﹤0.01% 1741
2021
Q3 		$2.4M Sell
124,612
-15,700
-11% -$313K ﹤0.01% 1799
2021
Q2 		$3.11M Buy
140,312
+8,172
+6% +$173K ﹤0.01% 1705
2021
Q1 		$3.47M Buy
132,140
+1,131
+0.9% +$26.9K ﹤0.01% 1613
2020
Q4 		$2.45M Buy
131,009
+5,273
+4% +$98.5K ﹤0.01% 1749
2020
Q3 		$2.13M Sell
125,736
-8,782
-7% -$171K ﹤0.01% 1649
2020
Q2 		$3.13M Sell
134,518
-16,722
-11% -$242K 0.01% 1467
2020
Q1 		$1.27M Buy
151,240
+4,902
+3% +$41.3K ﹤0.01% 1774
2019
Q4 		$1.43M Buy
146,338
+6,291
+4% +$59.1K ﹤0.01% 1929
2019
Q3 		$1.33M Buy
140,047
+7,381
+6% +$77.8K ﹤0.01% 1911
2019
Q2 		$1.58M Buy
132,666
+10,067
+8% +$121K ﹤0.01% 1865
2019
Q1 		$2.16M Buy
122,599
+312
+0.3% +$5.19K ﹤0.01% 1663
2018
Q4 		$2.12M Buy
122,287
+21,289
+21% +$363K ﹤0.01% 1609
2018
Q3 		$1.5M Sell
100,998
-3,206
-3% -$49.7K ﹤0.01% 1811
2018
Q2 		$1.66M Buy
104,204
+2,520
+2% +$37.6K ﹤0.01% 1774
2018
Q1 		$1.44M Buy
101,684
+3,130
+3% +$46.3K ﹤0.01% 1780
2017
Q4 		$1.38M Buy
98,554
+13,491
+16% +$197K ﹤0.01% 1802
2017
Q3 		$1.22M Sell
85,063
-57,906
-41% -$827K ﹤0.01% 1881
2017
Q2 		$2.25M Sell
142,969
-1,827
-1% -$26.3K 0.01% 1499
2017
Q1 		$2M Buy
144,796
+24,916
+21% +$348K ﹤0.01% 1547
2016
Q4 		$2.12M Buy
119,880
+811
+0.7% +$14.2K 0.01% 1413
2016
Q3 		$2.3M Sell
119,069
-3,155
-3% -$61.7K 0.01% 1316
2016
Q2 		$2.38M Buy
122,224
+940
+0.8% +$18.4K 0.01% 1230
2016
Q1 		$2.5M Buy
121,284
+3,610
+3% +$71.1K 0.01% 1220
2015
Q4 		$2.42M Buy
117,674
+4,925
+4% +$94.4K 0.01% 1229
2015
Q3 		$1.93M Sell
112,749
-4,756
-4% -$86.9K 0.01% 1344
2015
Q2 		$2.19M Sell
117,505
-4,225
-3% -$78.3K 0.01% 1336
2015
Q1 		$2.32M Buy
121,730
+24,100
+25% +$446K 0.01% 1305
2014
Q4 		$1.61M Sell
97,630
-4,510
-4% -$77.4K ﹤0.01% 1501
2014
Q3 		$1.81M Buy
102,140
+6,210
+6% +$122K 0.01% 1389
2014
Q2 		$1.98M Sell
95,930
-4,410
-4% -$90.6K 0.01% 1385
2014
Q1 		$2.19M Sell
100,340
-10,370
-9% -$238K 0.01% 1282
2013
Q4 		$2.94M Buy
110,710
+740
+0.7% +$18.2K 0.01% 1127
2013
Q3 		$2.6M Buy
109,970
+9,267
+9% +$216K 0.01% 1178
2013
Q2 		$2.17M Buy
+100,703
New +$2.17M 0.01% 1257

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

RhumbLine Advisers's VIVO Position: Q1 2023 in Review

RhumbLine Advisers sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 96,989 shares — an estimated $3.22M sold.

RhumbLine Advisers first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $3.48M in Q2 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • RhumbLine Advisers reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • RhumbLine Advisers sold 96,989 Meridian Bioscience Inc shares in Q1 2023, an estimated $3.22M.
  • RhumbLine Advisers first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • RhumbLine Advisers's Meridian Bioscience Inc position peaked at $3.48M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on RhumbLine Advisers's 13F filing for Q1 2023, filed 11 May 2023.